Why Nanobac?

Here is why Nanobac Pharmaceuticals is important for investors:

• Calcification and inflammation afflict most of our aging population. Nanobac Pharmaceuticals is the only company with patented methods to show that a tiny nanoparticle known commonly as nanobacteria produces a calcified coating which is the same material as found in disease-related calcified deposits.

• These nanobacteria have been discovered in the calcified deposits of heart disease, arthritis and kidney disease, as published in leading journals. See the Publications section of our website for information. This is the only credible scientific evidence of a particle that provokes calcification.

• Some critics have claimed that these particles are just inorganic crystals. However, the photographic evidence alone shows these nanoparticles have a different structure than inorganic crystals. On the left are inorganic calcium phosphate crystals with their jagged and jumbled surfaces. On the right are nanobacteria. There can be no mistaking the difference. Nanobacteria have been cultured and photographed by independent researchers around the world including at Mayo Clinic. (Click image to enlarge picture).

Commercial hydroxyl apatite (A) and nanobacteria culture (B). Top: SEM (scanning electron microscope) images of samples; bottom: Ca and P peaks detected by EDX (energy-dispersive X-ray) analysis

Calcification is a Disease Condition

• Most everyone gets calcification by the time they are seventy, and the process often starts when we are teenagers. It is a life-long disease process, yet its cause and cure have been mysteries to science.

• Calcification is documented in thousands of studies as causing blockages in arteries, inflammation in joints, and disruption to cells.

• Until now, no medical research has shown convincingly the cause of calcification. No process or organism has been found that produces these rock-hard calcified deposits under normal blood conditions.
  
  

Nanobac's Advantage in the Marketplace

• Any company that discovers a cause and effective treatment for calcification could be guaranteed powerful entry to markets because of the absence of effective treatment.

• Nanobac Pharmaceuticals has a compelling body of related intellectual property, including proprietary diagnostics in the marketplace now, that can recognize nanobacteria in blood and human tissue.

• Recently, these diagnostics have shown that nanobacteria bind disease-causing proteins in uniquely identifiable combinations, opening a potentially new door to early diagnosis and differentiation of diseases.

• Nanobac Pharmaceuticals has patented a range of drug combinations, consisting of well known and safe ingredients, shown convincingly to eradicate nanobacteria in vitro, as published by the U.S. Patent and Trade Office.

• Some drugs such as bisphosphonates have been marginally successful against certain forms of calcification, but the evidence is sketchy, and no permanent solution has been devised, so the marketplace is open.

• Since 2004, published studies have shown that some combinations patented by Nanobac are effective at treating atherosclerosis and prostatitis where no other treatments succeeded.

• From these studies, the company learned valuable information about patient compliance and drug effectiveness. No serious safety problems have been encountered. This let the company move to forward with another more effective drug combination.
  
  

The Nanobac Challenge

• In April 2006, Nanobac Pharmaceuticals embarked on a new program designed to determine the safety and effectiveness of a powerful new combination of well known drug ingredients. If successful, this program could save millions of patients from painful problems associated with Stage III prostatitis. And it may apply to many other calcifying diseases as well.

• Our challenge is to safely and effectively treat nanobacteria-related diseases. To do that we are also characterizing more accurately the disease-causing properties of these nanoparticles. The evidence suggests that we are on the right track.

• As shown in the Collaborations segment of our website, we are co-operating with leading research institutions to do this, and while our intellectual property gives us a powerful competitive edge, we are also working with the best in the business to develop practical applications.

Please contact us if you're interested to obtain an investors package.

Nanobac Pharmaceuticals, Inc.
3000 Bayport Drive, Suite 910
Tampa, Florida 33607
Ph. (813) 865-1125

Email us at: